DSE:ASIATICLAB

Asiatic Laboratories Limited research

Reports on Asiatic Laboratories Limited

Company · Analysis · 29 Oct 2026
Asiatic Laboratories: sales doubled in 9M FY2026 after a debt-funded plant upgrade, while 68% of the IPO money sat unused at June 2025
Nine-month revenue rose 99% to BDT 2,288m and EPS to BDT 3.97, but the company borrowed BDT 1.03bn in FY2025, BSEC extended the sponsors' lock-in over IPO-fund use and a planned 32-storey building, and the share price, BDT 108.0 on 29-Oct-2026, is 3.9 times its October 2024 low of BDT 27.8.

Asiatic Laboratories Limited (ALL) is a small Bangladeshi maker of branded generic medicines: tablets, capsules, oral liquids, powder for suspension, ophthalmic drops and injectables, made at one plant in the Tongi industrial area of Gazipur. It was incorporated in 1970, began commercial operation in 1998,…

Peer comparisons and industry research covering Asiatic Laboratories Limited

Company · DSE:IBP · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m
The Barishal-based tablet and capsule maker reported net losses of BDT 41.0m in FY2024 and BDT 36.8m in FY2025. Its auditor qualified the FY2025 accounts on four bases and reported a material uncertainty on going concern. Nine-month FY2026 revenue was BDT 134.8m, against BDT 76.9m a year earlier.

Indo-Bangla Pharmaceuticals PLC (IBP) makes and sells human-health medicines, excluding antibiotics, from a single factory at College Road, Barishal. The business traces to Indo-Pak Pharmaceutical Works, founded in 1954; it was privatised in 1982, incorporated as a private limited company on 18-Jun-2014, converted to a…

Company · DSE:PHARMAID · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Pharma Aids: FY2025 net sales of BDT 438m, 9M FY2026 sales up 17.6% and profit up 28.1%, sponsors at 19.38%
Bangladesh's listed maker of neutral glass ampoules for drug companies: seven years of filings, a 30.3% gross margin, BDT 27.3m of borrowings at June 2025, an auditor's opinion worded 'except for', and FY2026 results due to the board on 3-Nov-2026.

Pharma Aids Limited makes one product family: neutral glass ampoules, the small sealed glass containers that injectable medicines are filled into. It sells all of its output to pharmaceutical companies in Bangladesh in local currency and does not export; its main raw materials, neutral glass…

Company · DSE:TECHNODRUG · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Techno Drugs: FY2026 EPS of BDT 1.51 against 1.76, and BDT 129.8m of overdue loan interest disclosed in October 2026
The contraceptive supplier to the government reported FY2026 EPS of BDT 1.51 against 1.76, finance expenses at 11.2% of nine-month revenue, and told DSE in October 2026 that BDT 12.98 crore of loan interest was overdue; the board kept a 10% cash dividend for non-sponsor holders.

Techno Drugs Ltd. (TDL) makes human and veterinary medicines at two plants, at Satirpara in Narsingdi and at B.K. Bari, Mirzapur in Gazipur. It describes itself as the biggest supplier of injectable hormonal medicines to the government of Bangladesh, the fifth maker of contraceptive implants…

Company · DSE:NAVANAPHAR · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Navana Pharmaceuticals: sales up 28% and factories at 98% of capacity, but interest takes half of operating profit
FY2025 net sales rose 28.2% to BDT 8.84bn and operating profit 45.4%, yet finance expenses of BDT 750m left a 5.5% net margin. Borrowings fell from BDT 5.27bn to BDT 3.78bn by March 2026; FY2026 EPS was BDT 5.93.

Navana Pharmaceuticals PLC makes and sells generic medicines for people and animals in Bangladesh, and exports a small part of its output. Its fiscal year runs from 1 July to 30 June; FY2025 is the year to 30-Jun-2025. The company was incorporated in 1986, merged…

All Bangladesh research →